-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: BIF
It Takes a Village: The New Pharma-VC Model for Biotech Investing
High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >
BayBio Op-ed featured in Xconomy
Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology industry and the BIO Investor Forum in Xconomy: With more than 850 biotechnology companies, the Bay Area is the oldest, largest and most productive life sciences cluster in the world, employing more than 125,000 people in the region. For more than 30 years, this region has led the world in researching and delivering new cures and treatments for debilitating diseases Read More >
BIO Investor Forum – Raring to Go: The Race to Treat Ultra-Rare Diseases
The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline. In anticipation of an even more compelling opportunity, many companies are taking a step beyond and focusing on ultra rare diseases. Last week’s 11th Annual BIO Investor Forum in San Francisco hosted a panel, Raring Read More >
BIO Investor Forum: The New Kids on the Biotech Block
Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >
Cancer Stem Cell Therapy: Real Or Just Hype?
Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem cells of self-renewal and differentiation, thereby causing tumor relapse and/or metastatis. While traditional cancer treatments focus on tumor shrinkage, it’s a distinct possibility that these agents do not effectively destroy all of the CSCs, causing the tumor to reappear. The CSC theory is relatively new, so the treatment pipeline is still in its early stages. Nathan Sadeghi-Nejad, a contributor to Read More >
